AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05929768
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04694989
Drug: D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05694884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT05694884
Drug: ASLAN004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN004
Trial: NCT05905653
Drug: STN1012600 ophthalmic solution 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Trial: NCT05277051
Drug: GSK4381562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4381562 will be administered.
Trial: NCT05277051
Drug: GSK5764227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK5764227 will be administered.
Trial: NCT04740827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant matching placebo tablets.
Trial: NCT05223647
Drug: Chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Trial: NCT06685354
Drug: hepatic arterial infusion of recombinant human type 5 adenovirus
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
Trial: NCT06668727
Drug: HepB mAb19
RxNorm normalized name: HepB-CpG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD.
Trial: NCT05607680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously (SC) once a week.
Trial: NCT05607680
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 administered subcutaneously (SC) once a week.
Trial: NCT06684197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be used instead of dexmedetomidine
Trial: NCT04308278
Drug: 2LEBV® / 2LXFS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT04308278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT05709028
Drug: Standard of care antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
Trial: NCT05550909
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
Trial: NCT05887271
Drug: Low calorie meal replacement plan
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
Trial: NCT05181735
Drug: Eprex
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
Trial: NCT05802407
Drug: Later-line therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Trial: NCT06010693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
Trial: NCT05231772
Drug: Saccharomyces Boulardii Probiotic Supplement
RxNorm normalized name: Saccharomyces boulardii Chewable Tablet [Rezyst Probiotic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yeast
Trial: NCT05231772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05601323
Drug: Nal-IRI/FL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan, Fluorouracil, Levofolinate
Trial: NCT05601323
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
Trial: NCT05601323
Drug: Gem/nab-PTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, nab-Paclitaxel
Trial: NCT06619314
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06619314
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05194761
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using normal saline nebulization in neonates postextubation
Trial: NCT05212662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator supplied in vials identical to the active intervention, TTI-0102
Trial: NCT04356326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Trial: NCT06389760
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
Trial: NCT04603300
Drug: INT301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
Trial: NCT04905602
Drug: SHR-1905/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose
Trial: NCT05753865
Drug: SYHX2011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 260 mg/m\^2
Trial: NCT04603300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully functional toothpaste containing no immunotherapy agents
Trial: NCT05194306
Drug: Perla® Cold Preservation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
Trial: NCT05107492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: following a single subcutaneous dose of placebo
Trial: NCT04950920
Drug: Y-2 sublingual tablets
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg Edaravone+6mg d-borneo OR， Bid
Trial: NCT05831644
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 is an angiotensin II type 2 receptor agonist (ATRAG)
Trial: NCT05545514
Drug: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
Trial: NCT06509958
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034
Trial: NCT06651112
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
Trial: NCT00036140
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04699110
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group will receive adenosine (100 to 400 mcg)
Trial: NCT06620731
Drug: FCN-437c capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
Trial: NCT06684366
Drug: Statins (atorvastatin or simvastatin)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone
Trial: NCT05532852
Drug: standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-of-care
Trial: NCT06500819
Drug: B7-H3CART Dose (Intravenous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg
Trial: NCT05445232
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05445232
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05076032
Drug: OXO-001
RxNorm normalized name: 7-oxo-prasterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
Trial: NCT05076032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
Trial: NCT05922761
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Semi-synthetic macrolide antibiotic, taken orally
Trial: NCT06457074
Drug: Spironolactone Oral Tablet
RxNorm normalized name: spironolactone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Trial: NCT06137742
Drug: Placebo for PF-07868489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06263998
Drug: NCP112 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04429555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (5 matching capsules) twice daily for 7 days
Trial: NCT04666259
Drug: ABL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Trial: NCT04979780
Drug: Low molecular weight heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
Trial: NCT04979780
Drug: Direct Oral Anticoagulants (DOAC)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
Trial: NCT05534919
Drug: Nefecon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefecon is taken orally as capsules once daily for 9 months.
Trial: NCT06239532
Drug: HAIC+TAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
Trial: NCT05717049
Drug: Theophylline Tablets
RxNorm normalized name: Theophylline Tablets
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 week oral treatment
Trial: NCT05631093
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
Trial: NCT06231316
Drug: Norepinephrine Injection
RxNorm normalized name: norepinephrine Injection
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
Trial: NCT06683040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT06388616
Drug: Balcinrenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, Immediate release capsule to be taken orally.
Trial: NCT05278546
Drug: ILB2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Trial: NCT04990388
Drug: Antipyretic
RxNorm normalized name: ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive oral premedication prior to infusion
Trial: NCT05113771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04984226
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
Trial: NCT05700084
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
Trial: NCT06318988
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoactive drugs
Trial: NCT05929677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.
Trial: NCT04237103
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capsules taken once a week
Trial: NCT04237103
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered identically to the experimental group
Trial: NCT05137600
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
Trial: NCT04675450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Trial: NCT06193811
Drug: Avenciguat (BI 685509) (intended commercial formulation (iCF))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509) (intended commercial formulation (iCF))
Trial: NCT06193811
Drug: Avenciguat (BI 685509) (trial formulation 2 (TF2))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509) (trial formulation 2 (TF2))
Trial: NCT06094283
Drug: YCT-529
RxNorm normalized name: YCT-529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
Trial: NCT06094283
Drug: YCT-529 Placebo
RxNorm normalized name: YCT-529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YCT-529 Placebo
Trial: NCT06580366
Drug: Sennosid A+B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel Preparation
Trial: NCT06580366
Drug: Sodium Picosulfate/Magnesium Oxide/Citric Acid
RxNorm normalized name: sodium picosulfate/magnesium oxide/citric acid 10 mg-3.5 gram-12 gram ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel Preparation
Trial: NCT05670795
Drug: Recombinant Follicle Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical pregnancy rates
Trial: NCT05670795
Drug: Recombinant Follicle Stimulating Hormone and Clomiphene Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical pregnancy rates
Trial: NCT06194851
Drug: Saline nasal spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.
Trial: NCT05887258
Drug: Opioid free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.
Trial: NCT05887258
Drug: Opioid based Anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
Trial: NCT04956328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04787198
Drug: hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
Trial: NCT04787198
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
Trial: NCT05245578
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
Trial: NCT06144710
Drug: SG301 SC Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection every two weeks
Trial: NCT06355258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily